HiberGene’s PCR Adapt COVID-19 RT-qPCR is a CE marked multi-target SARS-CoV-2 test for nasopharyngeal (NP), oropharyngeal (OP) and anterior nasal swabs. This single tube assay is validated for both direct sample testing and manual/automated extraction.
Benefits of PCR Adapt:
- FAST accurate detection (55-70 mins)
- ACCURATE – 100% sensitivity, 100% specificity
- EASY – Low-complexity direct testing protocol available
- Multi-platform compatibility
- Automated extractors
- PCR systems 4
- High throughput capacity
- Kit Size: 64, 192 and 384
PCR Adapt COVID-19 has been evaluated in both Extracted and Direct formats with excellent concordance to the reference methods.
DIRECT:
A panel of 60 clinical specimens, comprising 30 negative and 30 positive anterior nasal swabs from individuals suspected of COVID-19 infection were collected using the Puritan Optiswab device and tested directly with PCR Adapt COVID-19 reagents.
EXTRACTED:
An independent clinical study of assay performance was carried out at Bons Secours Hospital, Cork. A panel of 251 combined nasopharyngeal and throat swab specimens were extracted using the KingFisher Flex System and the MagMAX Viral/Pathogen II Nucleic Acid Isolation Kit. Samples were tested using Hibergene PCR Adapt COVID-19 reagents on the BioRad CFX96 and the results compared to those obtained with independently validated commercial PCR kit.
Product Features:
Direct RT-qPCR Method:
1 TAT – Turn around time,
2 Sensitivity, 3 Specificity, 4 Adapt 48, QuantStudio, BioRad CfX line, Roche light
cycler, MyGO or similar
